Advancing Knowledge of Acute Cutaneous Graft-Versus-Host Disease Wound Care: A Case Study
Summary: Published in the January/February 2026 issue of the Journal of Wound, Ostomy and Continence Nursing (JWOCN, Vol. 53, No. 1, pp. 59–63; DOI: 10.1097/WON.0000000000001240), this case study addresses a wound management scenario encountered increasingly in oncology and bone marrow transplant units: acute cutaneous graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (HSCT). Acute cutaneous GvHD is a frequent and potentially life-threatening complication of allogeneic HSCT in which donor immune cells attack the recipient’s tissues, manifesting in the skin as erythema, blistering, and epidermal sloughing that can mimic severe burn injuries. Despite its prevalence, no well-established wound management guidelines exist for this condition. The case subject, Mr. T, was a 64-year-old male with acute myeloid leukemia with myelodysplasia-related changes who received an allogeneic human leukocyte antigen-matched HSCT. Seventy-five days post-transplant, he developed extensive wounds on his upper and lower limbs, part of his chest, torso, and sacrum consistent with a grade IV stage 4 presentation — the most severe classification. Systemic management involved four sequential or overlapping lines of therapy: systemic corticosteroids, tacrolimus combined with extracorporeal photopheresis (ECP), etanercept, and ruxolitinib (a JAK inhibitor increasingly used for steroid-refractory GvHD). Throughout, topical wound management used advanced dressings incorporating soft silicone layers — selected for their atraumatic removal properties, which are particularly important in fragile GvHD-affected skin prone to mechanical disruption. Wounds resolved by day 109 post-HSCT. The authors conclude that soft silicone layer dressings represent a practical and effective component of wound care in this setting, while emphasising the need for larger-scale studies to establish definitive evidence-based recommendations.
Key Highlights:
- Clinical context: acute cutaneous GvHD is a frequent complication of allogeneic HSCT (a growing cancer treatment modality); grade IV stage 4 presentation involves extensive, severe skin wounds that closely resemble burns and lack established wound management protocols
- Patient case: 64-year-old male with AML; extensive wounds on limbs, chest, torso, and sacrum developing 75 days post-HSCT; managed across four systemic therapy lines (corticosteroids → tacrolimus + ECP → etanercept → ruxolitinib) with concurrent wound care
- Wound management approach: soft silicone layer advanced dressings selected for atraumatic removal — critical in GvHD-affected skin where mechanical disruption can worsen epithelial integrity and patient pain; full wound resolution achieved by day 109
- Ruxolitinib (JAK inhibitor): highlighted as an emerging systemic agent for steroid-refractory acute GvHD; wound teams managing oncology patients should be aware of its role and potential cutaneous response timeline
- Gap in evidence: the authors explicitly note that no well-established wound management recommendations currently exist for cutaneous GvHD; this case contributes to a limited evidence base and underscores the need for prospective, multi-patient studies
- Multidisciplinary care model: effective management required coordination between transplant medicine, dermatology, and wound/ostomy nursing — a model that may inform future guidelines for complex oncology-associated skin wounds
Keywords: graft versus host disease wound care, allogeneic HSCT skin wound, soft silicone dressing oncology, acute GvHD skin management, ruxolitinib wound healing, oncology wound care nursing